Trials / Approved For Marketing
Approved For MarketingNCT00650390
Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore the safety of adalimumab in subjects previously treated with infliximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | 40 mg adalimumab every other week |
Timeline
- First posted
- 2008-04-01
- Last updated
- 2008-04-01
Source: ClinicalTrials.gov record NCT00650390. Inclusion in this directory is not an endorsement.